DaVita (NYSE:DVA) Shares Down 4.2% - Should You Sell?

DaVita Inc. (NYSE:DVA - Get Free Report) traded down 4.2% during trading on Monday . The stock traded as low as $147.81 and last traded at $148.99. 169,539 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 821,029 shares. The stock had previously closed at $155.51.

Analyst Ratings Changes

DVA has been the topic of several recent research reports. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research note on Friday, February 21st. Cowen reissued a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, DaVita currently has an average rating of "Hold" and an average target price of $166.33.

DaVita Stock Performance

The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a 50 day moving average of $149.13 and a two-hundred day moving average of $156.02. The stock has a market cap of $11.22 billion, a P/E ratio of 13.05, a P/E/G ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, research analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Epoch Investment Partners Inc. bought a new position in DaVita in the fourth quarter worth $55,100,000. Invesco Ltd. increased its stake in DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after acquiring an additional 275,284 shares during the period. Iron Triangle Partners LP acquired a new position in DaVita in the fourth quarter worth about $38,946,000. Amundi boosted its holdings in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after purchasing an additional 240,126 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of DaVita by 14,695.8% during the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock worth $35,919,000 after buying an additional 233,222 shares during the period. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.